PROCEPT BioRobotics (PRCT) Financials

$37.14 -1.50 (-3.88%)

Closing price 04:00 PM Eastern

Extended Trading

$37.30 +0.16 (+0.43%)

As of 06:15 PM Eastern

Annual Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-53	-60	-87	-106	-91
Consolidated Net Income / (Loss)	-53	-60	-87	-106	-91
Net Income / (Loss) Continuing Operations	-53	-60	-87	-106	-91
Total Pre-Tax Income	-53	-60	-87	-106	-91
Total Operating Income	-48	-54	-81	-109	-97
Total Gross Profit	-1.26	16	37	71	137
Total Revenue	7.72	34	75	136	224
Operating Revenue	-	34	75	136	224
Total Cost of Revenue	8.97	19	38	65	87
Operating Cost of Revenue	8.97	19	38	65	87
Total Operating Expenses	47	70	118	180	234
Selling, General & Admin Expense	30	51	89	132	171
Research & Development Expense	16	19	29	48	62
Total Other Income / (Expense), net	-5.22	-5.69	-6.43	3.27	5.20
Interest Expense	5.26	5.81	8.44	4.00	4.18
Other Income / (Expense), net	0.04	0.12	2.01	7.27	9.39
Basic Earnings per Share	($14.47)	($3.63)	($1.96)	($2.24)	($1.75)
Weighted Average Basic Shares Outstanding	3.66M	16.48M	44.40M	47.26M	52.13M
Diluted Earnings per Share	($14.47)	($3.63)	($1.96)	($2.24)	($1.75)
Weighted Average Diluted Shares Outstanding	3.66M	16.48M	44.40M	47.26M	52.13M
Weighted Average Basic & Diluted Shares Outstanding	-	43.99M	44.87M	50.96M	54.82M

This table shows PROCEPT BioRobotics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Consolidated Net Income / (Loss)	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Net Income / (Loss) Continuing Operations	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Total Pre-Tax Income	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Total Operating Income	-22	-25	-28	-26	-26	-30	-28	-27	-22	-20	-27
Total Gross Profit	10	11	12	18	19	21	25	31	37	44	44
Total Revenue	20	24	24	33	35	44	45	53	58	68	69
Operating Revenue	20	24	24	33	35	44	45	53	58	68	69
Total Cost of Revenue	10	13	12	15	16	22	20	22	21	25	25
Operating Cost of Revenue	10	13	12	15	16	22	20	22	21	25	25
Total Operating Expenses	32	36	41	44	44	51	53	58	59	63	72
Selling, General & Admin Expense	25	26	30	32	33	36	40	41	43	48	55
Research & Development Expense	7.58	9.68	11	12	12	14	13	18	17	15	16
Total Other Income / (Expense), net	-0.51	-3.13	-0.11	0.34	0.99	2.05	1.69	1.20	1.45	0.85	2.70
Interest Expense	1.46	4.12	0.89	0.97	1.02	1.13	1.05	1.03	1.14	0.97	0.88
Other Income / (Expense), net	0.95	0.99	0.78	1.31	2.01	3.18	2.74	2.23	2.59	1.82	3.58
Basic Earnings per Share	($0.51)	($0.63)	($0.63)	($0.56)	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)
Weighted Average Basic Shares Outstanding	44.64M	44.40M	45.07M	45.16M	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M
Diluted Earnings per Share	($0.51)	($0.63)	($0.63)	($0.56)	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)
Weighted Average Diluted Shares Outstanding	44.64M	44.40M	45.07M	45.16M	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M
Weighted Average Basic & Diluted Shares Outstanding	44.72M	44.87M	45.05M	45.28M	50.50M	50.96M	51.42M	51.93M	52.18M	54.82M	55.33M

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	58	204	-79	35	77
Net Cash From Operating Activities	-48	-57	-80	-108	-99
Net Cash From Continuing Operating Activities	-48	-57	-80	-108	-99
Net Income / (Loss) Continuing Operations	-53	-60	-87	-106	-91
Consolidated Net Income / (Loss)	-53	-60	-87	-106	-91
Depreciation Expense	2.86	-	2.84	3.81	5.23
Non-Cash Adjustments To Reconcile Net Income	2.30	3.90	15	25	34
Changes in Operating Assets and Liabilities, net	-0.48	-4.71	-11	-31	-47
Net Cash From Investing Activities	-0.23	-0.59	-2.65	-25	-4.41
Net Cash From Continuing Investing Activities	-0.23	-0.59	-2.65	-25	-4.41
Purchase of Property, Plant & Equipment	-0.23	-0.59	-2.65	-25	-4.41
Net Cash From Financing Activities	107	262	3.61	168	180
Net Cash From Continuing Financing Activities	107	262	3.61	168	180
Repayment of Debt	-	0.00	-51	0.00	0.00
Issuance of Debt	25	0.00	54	3.61	4.53
Issuance of Common Equity	0.00	172	0.00	162	165
Other Financing Activities, net	5.60	5.04	1.01	2.48	11
Cash Interest Paid	3.97	4.75	4.29	4.06	3.97

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-21	-27	-41	-31	137	-31	-32	-11	-17	137	-18
Net Cash From Operating Activities	-20	-25	-36	-28	-19	-25	-32	-16	-19	-32	-17
Net Cash From Continuing Operating Activities	-20	-25	-36	-28	-19	-25	-32	-16	-19	-32	-17
Net Income / (Loss) Continuing Operations	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Consolidated Net Income / (Loss)	-23	-28	-28	-25	-25	-28	-26	-26	-21	-19	-25
Depreciation Expense	0.70	0.66	0.79	0.64	1.05	1.32	1.18	1.27	1.33	1.45	1.48
Non-Cash Adjustments To Reconcile Net Income	4.15	6.95	7.66	6.88	5.72	4.87	8.76	8.80	9.25	7.38	11
Changes in Operating Assets and Liabilities, net	-2.09	-4.62	-16	-11	-1.09	-3.48	-16	-0.18	-8.40	-22	-4.33
Net Cash From Investing Activities	-1.51	-0.87	-5.34	-5.37	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84
Net Cash From Continuing Investing Activities	-1.51	-0.87	-5.34	-5.37	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84
Purchase of Property, Plant & Equipment	-1.51	-0.87	-5.34	-5.37	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84
Net Cash From Financing Activities	0.78	-1.32	0.38	2.43	162	2.87	2.59	5.30	1.72	171	1.30
Net Cash From Continuing Financing Activities	0.78	-1.32	0.38	2.43	162	2.87	2.59	5.30	1.72	171	1.30
Other Financing Activities, net	0.78	-2.63	0.38	0.71	0.41	0.97	2.59	3.17	1.72	3.60	1.30
Cash Interest Paid	1.20	0.72	1.12	0.94	0.99	1.00	1.00	1.03	1.01	0.92	0.89

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	126	337	309	405	534
Total Current Assets	110	326	273	351	482
Cash & Equivalents	100	304	222	257	334
Accounts Receivable	1.55	4.46	15	48	83
Inventories, net	6.92	13	29	40	56
Prepaid Expenses	1.65	4.24	6.18	5.21	8.45
Plant, Property, & Equipment, net	8.27	5.05	8.66	29	27
Total Noncurrent Assets	7.44	5.81	28	25	25
Goodwill	2.02	1.75	1.48	1.20	0.93
Other Noncurrent Operating Assets	5.42	4.06	27	24	25
Total Liabilities & Shareholders' Equity	126	337	309	405	534
Total Liabilities	65	70	112	124	132
Total Current Liabilities	15	16	35	46	53
Accounts Payable	1.24	2.03	9.39	13	10
Accrued Expenses	4.64	6.48	13	17	22
Current Deferred Revenue	0.23	1.03	2.86	5.66	9.57
Other Current Liabilities	3.86	6.71	9.60	9.89	12
Total Noncurrent Liabilities	50	54	77	78	79
Long-Term Debt	44	50	51	51	51
Other Noncurrent Operating Liabilities	6.08	3.69	26	27	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-183	267	197	281	402
Total Preferred & Common Equity	-183	267	197	281	402
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-183	267	197	281	402
Common Stock	19	529	546	735	948
Retained Earnings	-202	-262	-349	-455	-546
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.05	-0.01	0.08	0.11

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	324	284	272	421	383	374	374	519
Total Current Assets	289	246	230	369	329	322	323	466
Cash & Equivalents	249	181	150	287	226	214	197	316
Accounts Receivable	13	21	33	35	56	59	69	79
Inventories, net	22	39	43	42	42	44	51	62
Prepaid Expenses	4.52	4.26	3.74	3.98	5.91	5.02	6.32	7.99
Plant, Property, & Equipment, net	5.12	12	16	27	28	28	27	28
Total Noncurrent Assets	30	27	26	25	25	25	25	25
Goodwill	1.55	1.41	1.34	1.27	1.14	1.07	1.00	0.86
Other Noncurrent Operating Assets	28	26	25	24	24	24	24	25
Total Liabilities & Shareholders' Equity	324	284	272	421	383	374	374	519
Total Liabilities	103	111	117	122	119	123	133	130
Total Current Liabilities	27	33	36	41	39	43	54	52
Short-Term Debt	2.47	3.00	-	-	1.70	-	-	1.98
Accounts Payable	6.33	10	10	14	10	9.95	15	15
Accrued Expenses	10	7.41	9.95	13	11	15	19	15
Current Deferred Revenue	2.34	3.94	4.72	5.01	5.86	6.55	7.99	9.80
Other Current Liabilities	5.93	7.81	11	9.49	9.54	11	12	10
Total Noncurrent Liabilities	76	79	81	80	80	80	79	78
Long-Term Debt	51	51	51	51	51	51	51	51
Other Noncurrent Operating Liabilities	25	28	29	29	29	28	28	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	221	173	156	299	264	252	241	389
Total Preferred & Common Equity	221	173	156	299	264	252	241	389
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	221	173	156	299	264	252	241	389
Common Stock	541	550	558	726	744	758	768	960
Retained Earnings	-321	-377	-402	-427	-481	-506	-527	-571
Accumulated Other Comprehensive Income / (Loss)	0.22	0.02	-0.01	-0.01	0.11	-0.00	-0.02	0.22

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	346.72%	117.60%	81.55%	64.84%
EBITDA Growth	0.00%	-12.96%	-49.59%	-29.29%	16.41%
EBIT Growth	0.00%	-13.16%	-45.65%	-29.46%	14.40%
NOPAT Growth	0.00%	-13.31%	-49.04%	-35.24%	11.50%
Net Income Growth	0.00%	-12.89%	-45.61%	-21.51%	13.68%
EPS Growth	0.00%	74.91%	46.01%	-14.29%	21.88%
Operating Cash Flow Growth	0.00%	-18.60%	-40.20%	-34.36%	8.14%
Free Cash Flow Firm Growth	0.00%	0.00%	-69.63%	-81.09%	10.28%
Invested Capital Growth	0.00%	30.52%	100.78%	191.90%	60.24%
Revenue Q/Q Growth	0.00%	0.00%	22.22%	17.02%	12.34%
EBITDA Q/Q Growth	0.00%	0.00%	-6.01%	1.48%	14.34%
EBIT Q/Q Growth	0.00%	0.00%	-9.98%	-2.34%	8.87%
NOPAT Q/Q Growth	0.00%	0.00%	-11.32%	-4.32%	9.25%
Net Income Q/Q Growth	0.00%	0.00%	-12.70%	0.63%	8.64%
EPS Q/Q Growth	0.00%	0.00%	-229.80%	3.86%	10.26%
Operating Cash Flow Q/Q Growth	0.00%	-5.58%	-12.13%	0.35%	-8.29%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-12.84%	-4.75%
Invested Capital Q/Q Growth	0.00%	0.00%	3.80%	19.22%	25.10%
Profitability Metrics	-	-	-	-	-
Gross Margin	-16.26%	46.02%	49.44%	52.17%	61.07%
EBITDA Margin	-581.81%	-147.13%	-101.14%	-72.03%	-36.52%
Operating Margin	-619.44%	-157.12%	-107.61%	-80.16%	-43.04%
EBIT Margin	-618.87%	-156.77%	-104.93%	-74.82%	-38.86%
Profit (Net Income) Margin	-687.04%	-173.62%	-116.18%	-77.76%	-40.72%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	111.02%	110.75%	110.72%	103.92%	104.80%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-341.86%	-336.08%	-294.12%	-152.05%	-69.42%
ROIC Less NNEP Spread (ROIC-NNEP)	-303.64%	-321.72%	-279.73%	-136.42%	-59.68%
Return on Net Nonoperating Assets (RNNOA)	254.89%	299.59%	256.57%	107.73%	42.65%
Return on Equity (ROE)	-86.97%	-36.49%	-37.55%	-44.32%	-26.77%
Cash Return on Invested Capital (CROIC)	0.00%	-362.56%	-361.13%	-249.98%	-115.72%
Operating Return on Assets (OROA)	-37.91%	-23.35%	-24.36%	-28.54%	-18.58%
Return on Assets (ROA)	-42.09%	-25.85%	-26.97%	-29.66%	-19.48%
Return on Common Equity (ROCE)	260.94%	-9.37%	-37.55%	-44.32%	-26.77%
Return on Equity Simple (ROE_SIMPLE)	28.99%	-22.41%	-44.22%	-37.72%	-22.73%
Net Operating Profit after Tax (NOPAT)	-33	-38	-57	-76	-68
NOPAT Margin	-433.61%	-109.98%	-75.33%	-56.11%	-30.12%
Net Nonoperating Expense Percent (NNEP)	-38.22%	-14.36%	-14.40%	-15.63%	-9.74%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-22.76%	-23.01%	-14.91%
Cost of Revenue to Revenue	116.26%	53.98%	50.56%	47.83%	38.93%
SG&A Expenses to Revenue	392.28%	148.05%	118.42%	96.76%	76.35%
R&D to Revenue	210.90%	55.10%	38.63%	35.57%	27.75%
Operating Expenses to Revenue	603.17%	203.14%	157.05%	132.33%	104.10%
Earnings before Interest and Taxes (EBIT)	-48	-54	-79	-102	-87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-45	-51	-76	-98	-82
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	4.07	9.43	7.54	10.45
Price to Tangible Book Value (P/TBV)	0.00	4.10	9.50	7.57	10.47
Price to Revenue (P/Rev)	17.82	31.56	24.76	15.54	18.72
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	33.73	65.25	65.74	25.52	32.67
Enterprise Value to Revenue (EV/Rev)	42.79	24.18	22.48	14.03	17.46
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.80	0.19	0.26	0.18	0.13
Long-Term Debt to Equity	0.73	0.19	0.26	0.18	0.13
Financial Leverage	-0.84	-0.93	-0.92	-0.79	-0.71
Leverage Ratio	2.07	1.41	1.39	1.49	1.37
Compound Leverage Factor	2.29	1.56	1.54	1.55	1.44
Debt to Total Capital	44.54%	15.77%	20.63%	15.46%	11.35%
Short-Term Debt to Total Capital	4.14%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	40.40%	15.77%	20.63%	15.46%	11.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	221.85%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-166.39%	84.23%	79.37%	84.54%	88.65%
Debt to EBITDA	-1.09	-0.99	-0.68	-0.52	-0.63
Net Debt to EBITDA	1.14	5.01	2.26	2.10	3.44
Long-Term Debt to EBITDA	-0.99	-0.99	-0.68	-0.52	-0.63
Debt to NOPAT	-1.46	-1.32	-0.91	-0.67	-0.76
Net Debt to NOPAT	1.53	6.71	3.03	2.69	4.17
Long-Term Debt to NOPAT	-1.33	-1.32	-0.91	-0.67	-0.76
Altman Z-Score	-1.25	8.92	8.67	9.08	18.54
Noncontrolling Interest Sharing Ratio	400.02%	74.33%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	7.59	20.08	7.73	7.63	9.07
Quick Ratio	7.00	19.01	6.72	6.65	7.85
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-41	-69	-126	-113
Operating Cash Flow to CapEx	-20,748.07%	-9,684.80%	-3,029.85%	-428.48%	-2,250.24%
Free Cash Flow to Firm to Interest Expense	0.00	-7.04	-8.22	-31.45	-26.94
Operating Cash Flow to Interest Expense	-9.19	-9.87	-9.52	-27.03	-23.71
Operating Cash Flow Less CapEx to Interest Expense	-9.23	-9.97	-9.84	-33.34	-24.77
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.06	0.15	0.23	0.38	0.48
Accounts Receivable Turnover	4.98	11.47	7.60	4.28	3.40
Inventory Turnover	1.30	1.85	1.82	1.91	1.82
Fixed Asset Turnover	0.93	5.18	10.95	7.28	8.10
Accounts Payable Turnover	7.24	11.38	6.64	5.69	7.43
Days Sales Outstanding (DSO)	73.26	31.83	48.02	85.29	107.20
Days Inventory Outstanding (DIO)	281.68	196.85	200.60	191.34	200.30
Days Payable Outstanding (DPO)	50.45	32.06	54.95	64.13	49.14
Cash Conversion Cycle (CCC)	304.50	196.62	193.66	212.51	258.37
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	9.79	13	26	75	120
Invested Capital Turnover	0.79	3.06	3.90	2.71	2.30
Increase / (Decrease) in Invested Capital	0.00	2.99	13	49	45
Enterprise Value (EV)	330	834	1,686	1,911	3,920
Market Capitalization	138	1,088	1,858	2,116	4,202
Book Value per Share	($49.93)	$6.14	$4.41	$5.56	$7.71
Tangible Book Value per Share	($50.48)	$6.10	$4.37	$5.54	$7.69
Total Capital	110	317	248	332	454
Total Debt	49	50	51	51	51
Total Long-Term Debt	44	50	51	51	51
Net Debt	-51	-254	-171	-206	-282
Capital Expenditures (CapEx)	0.23	0.59	2.65	25	4.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.15	5.61	15	47	95
Debt-free Net Working Capital (DFNWC)	100	310	237	305	429
Net Working Capital (NWC)	96	310	237	305	429
Net Nonoperating Expense (NNE)	20	22	31	29	24
Net Nonoperating Obligations (NNO)	-51	-254	-171	-206	-282
Total Depreciation and Amortization (D&A)	2.86	3.32	2.84	3.81	5.23
Debt-free, Cash-free Net Working Capital to Revenue	1.96%	16.28%	19.60%	34.82%	42.31%
Debt-free Net Working Capital to Revenue	1,299.48%	899.05%	316.39%	223.69%	190.96%
Net Working Capital to Revenue	1,240.51%	899.05%	316.39%	223.69%	190.96%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($3.63)	($1.96)	($2.24)	($1.75)
Adjusted Weighted Average Basic Shares Outstanding	0.00	16.48M	44.40M	47.26M	52.13M
Adjusted Diluted Earnings per Share	$0.00	($3.63)	($1.96)	($2.24)	($1.75)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	16.48M	44.40M	47.26M	52.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	43.99M	44.87M	50.96M	54.82M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-38	-57	-76	-68
Normalized NOPAT Margin	-433.61%	-109.98%	-75.33%	-56.11%	-30.12%
Pre Tax Income Margin	-687.04%	-173.62%	-116.18%	-77.76%	-40.72%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-9.08	-9.30	-9.33	-25.51	-20.85
NOPAT to Interest Expense	-6.36	-6.53	-6.69	-19.13	-16.16
EBIT Less CapEx to Interest Expense	-9.12	-9.40	-9.64	-31.82	-21.90
NOPAT Less CapEx to Interest Expense	-6.40	-6.63	-7.01	-25.44	-17.22
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	134.76%	134.56%	71.90%	98.33%	72.50%	83.29%	82.51%	61.17%	66.29%	56.57%	55.28%
EBITDA Growth	-72.79%	-38.32%	-78.63%	-39.07%	-10.24%	-7.18%	11.48%	1.48%	17.93%	34.43%	5.66%
EBIT Growth	-67.47%	-42.24%	-75.07%	-37.07%	-11.56%	-9.70%	9.73%	-1.13%	15.97%	32.20%	4.22%
NOPAT Growth	-72.74%	-48.77%	-80.70%	-43.36%	-15.85%	-18.05%	2.57%	-4.69%	12.43%	33.32%	0.76%
Net Income Growth	-60.34%	-53.54%	-65.75%	-31.80%	-8.88%	2.36%	8.87%	-1.35%	14.82%	31.45%	4.70%
EPS Growth	58.20%	-122.18%	-61.54%	-30.23%	0.00%	14.29%	19.05%	10.71%	21.57%	37.04%	11.76%
Operating Cash Flow Growth	-55.68%	-52.79%	-97.07%	-65.47%	4.57%	1.51%	10.14%	44.47%	0.75%	-30.65%	47.41%
Free Cash Flow Firm Growth	-28.06%	0.00%	-57.41%	-51.47%	-103.00%	-129.96%	-39.60%	2.55%	12.89%	15.76%	17.14%
Invested Capital Growth	96.27%	100.78%	143.73%	156.06%	154.14%	191.90%	100.68%	57.10%	52.70%	60.24%	38.11%
Revenue Q/Q Growth	21.92%	16.85%	2.64%	35.65%	6.04%	24.16%	2.20%	19.79%	9.40%	16.90%	1.36%
EBITDA Q/Q Growth	-20.14%	-14.32%	-11.46%	11.67%	4.77%	-11.15%	10.06%	1.69%	20.67%	11.20%	-36.21%
EBIT Q/Q Growth	-19.25%	-13.66%	-14.76%	11.88%	2.95%	-11.77%	5.57%	1.27%	19.36%	9.82%	-33.39%
NOPAT Q/Q Growth	-23.66%	-13.28%	-13.33%	9.70%	0.06%	-15.42%	6.46%	2.97%	16.40%	12.11%	-39.21%
Net Income Q/Q Growth	-17.87%	-24.58%	-1.11%	11.23%	2.62%	-11.71%	5.63%	1.28%	18.15%	10.10%	-31.19%
EPS Q/Q Growth	-18.60%	-23.53%	0.00%	11.11%	8.93%	-5.88%	5.56%	1.96%	20.00%	15.00%	-32.35%
Operating Cash Flow Q/Q Growth	-15.91%	-26.81%	-42.72%	21.12%	33.16%	-30.88%	-30.22%	51.26%	-19.47%	-72.29%	47.58%
Free Cash Flow Firm Q/Q Growth	20.39%	-10.18%	-53.82%	-12.27%	-6.70%	-24.81%	6.62%	21.63%	4.63%	-20.70%	8.15%
Invested Capital Q/Q Growth	11.57%	3.80%	77.85%	24.32%	10.74%	19.22%	22.27%	-2.68%	7.64%	25.10%	5.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.28%	44.90%	51.18%	55.67%	53.77%	48.77%	56.21%	59.01%	63.24%	64.00%	63.85%
EBITDA Margin	-100.52%	-98.35%	-109.84%	-71.53%	-64.24%	-57.51%	-53.27%	-43.72%	-31.70%	-24.08%	-32.37%
Operating Margin	-108.63%	-105.31%	-116.28%	-77.41%	-72.96%	-67.83%	-62.08%	-50.28%	-38.42%	-28.89%	-39.67%
EBIT Margin	-103.98%	-101.14%	-113.09%	-73.47%	-67.24%	-60.53%	-55.93%	-46.10%	-33.98%	-26.21%	-34.50%
Profit (Net Income) Margin	-111.13%	-118.48%	-116.72%	-76.38%	-70.14%	-63.11%	-58.28%	-48.03%	-35.93%	-27.63%	-35.77%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	106.88%	117.15%	103.21%	103.97%	104.32%	104.26%	104.19%	104.19%	105.75%	105.42%	103.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-250.24%	-287.84%	-215.65%	-139.67%	-135.84%	-128.65%	-99.05%	-85.26%	-67.74%	-46.60%	-63.48%
ROIC Less NNEP Spread (ROIC-NNEP)	-247.18%	-282.84%	-210.88%	-135.03%	-132.75%	-125.04%	-94.65%	-80.03%	-64.98%	-44.52%	-60.94%
Return on Net Nonoperating Assets (RNNOA)	228.89%	259.42%	179.03%	108.08%	110.41%	98.74%	64.96%	51.41%	45.90%	31.82%	40.60%
Return on Equity (ROE)	-21.35%	-28.41%	-36.62%	-31.60%	-25.43%	-29.92%	-34.10%	-33.85%	-21.84%	-14.77%	-22.88%
Cash Return on Invested Capital (CROIC)	0.00%	-361.13%	-286.88%	-267.23%	-254.48%	-249.98%	-177.66%	-149.70%	-135.63%	-115.72%	-93.93%
Operating Return on Assets (OROA)	-18.89%	-23.48%	-31.84%	-25.60%	-21.00%	-23.09%	-26.20%	-25.17%	-17.08%	-12.54%	-19.05%
Return on Assets (ROA)	-20.19%	-27.50%	-32.86%	-26.61%	-21.91%	-24.08%	-27.30%	-26.22%	-18.06%	-13.22%	-19.75%
Return on Common Equity (ROCE)	-21.35%	-28.41%	-36.62%	-31.60%	-25.43%	-29.92%	-34.10%	-33.85%	-21.84%	-14.77%	-22.88%
Return on Equity Simple (ROE_SIMPLE)	-35.03%	0.00%	-56.87%	-67.06%	-35.60%	0.00%	-39.15%	-41.19%	-41.48%	0.00%	-23.18%
Net Operating Profit after Tax (NOPAT)	-15	-18	-20	-18	-18	-21	-19	-19	-16	-14	-19
NOPAT Margin	-76.04%	-73.72%	-81.40%	-54.19%	-51.07%	-47.48%	-43.45%	-35.20%	-26.90%	-20.22%	-27.77%
Net Nonoperating Expense Percent (NNEP)	-3.06%	-5.00%	-4.77%	-4.65%	-3.10%	-3.61%	-4.40%	-5.23%	-2.76%	-2.07%	-2.54%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.06%	-	-	-	-6.23%	-	-	-	-3.04%	-4.34%
Cost of Revenue to Revenue	49.72%	55.10%	48.82%	44.33%	46.23%	51.23%	43.79%	40.99%	36.76%	36.00%	36.15%
SG&A Expenses to Revenue	121.65%	109.49%	123.47%	98.00%	93.68%	83.33%	88.91%	76.49%	73.14%	70.81%	79.81%
R&D to Revenue	37.26%	40.72%	44.00%	35.08%	33.05%	33.26%	29.38%	32.80%	28.52%	22.08%	23.72%
Operating Expenses to Revenue	158.91%	150.21%	167.46%	133.08%	126.73%	116.60%	118.29%	109.29%	101.66%	92.89%	103.52%
Earnings before Interest and Taxes (EBIT)	-21	-24	-28	-24	-24	-26	-25	-25	-20	-18	-24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-23	-27	-24	-23	-25	-24	-23	-19	-16	-22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.37	9.43	7.36	10.21	4.96	7.54	9.45	12.48	17.25	10.45	8.21
Price to Tangible Book Value (P/TBV)	8.43	9.50	7.42	10.30	4.98	7.57	9.49	12.53	17.32	10.47	8.23
Price to Revenue (P/Rev)	30.12	24.76	14.95	15.67	12.76	15.54	15.96	17.79	20.82	18.72	12.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	66.89	65.74	25.14	26.33	19.89	25.52	25.38	33.44	41.87	32.67	23.18
Enterprise Value to Revenue (EV/Rev)	26.93	22.48	13.46	14.69	10.73	14.03	14.86	16.87	20.09	17.46	11.77
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.24	0.26	0.31	0.33	0.17	0.18	0.20	0.20	0.21	0.13	0.14
Long-Term Debt to Equity	0.23	0.26	0.30	0.33	0.17	0.18	0.19	0.20	0.21	0.13	0.13
Financial Leverage	-0.93	-0.92	-0.85	-0.80	-0.83	-0.79	-0.69	-0.64	-0.71	-0.71	-0.67
Leverage Ratio	1.34	1.39	1.42	1.48	1.43	1.49	1.53	1.59	1.47	1.37	1.38
Compound Leverage Factor	1.43	1.63	1.47	1.54	1.49	1.56	1.59	1.65	1.56	1.45	1.43
Debt to Total Capital	19.41%	20.63%	23.86%	24.75%	14.63%	15.46%	16.74%	16.95%	17.58%	11.35%	12.08%
Short-Term Debt to Total Capital	0.90%	0.00%	1.32%	0.00%	0.00%	0.00%	0.54%	0.00%	0.00%	0.00%	0.45%
Long-Term Debt to Total Capital	18.51%	20.63%	22.54%	24.75%	14.63%	15.46%	16.20%	16.95%	17.58%	11.35%	11.63%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.59%	79.37%	76.14%	75.25%	85.37%	84.54%	83.26%	83.05%	82.42%	88.65%	87.92%
Debt to EBITDA	-0.74	-0.68	-0.60	-0.53	-0.52	-0.52	-0.53	-0.52	-0.54	-0.63	-0.66
Net Debt to EBITDA	2.74	2.26	1.41	1.02	2.38	2.10	1.74	1.64	1.52	3.44	3.26
Long-Term Debt to EBITDA	-0.71	-0.68	-0.57	-0.53	-0.52	-0.52	-0.52	-0.52	-0.54	-0.63	-0.64
Debt to NOPAT	-1.05	-0.91	-0.83	-0.72	-0.70	-0.67	-0.70	-0.67	-0.69	-0.76	-0.79
Net Debt to NOPAT	3.86	3.03	1.95	1.40	3.23	2.69	2.27	2.12	1.95	4.17	3.89
Long-Term Debt to NOPAT	-1.00	-0.91	-0.78	-0.72	-0.70	-0.67	-0.68	-0.67	-0.69	-0.76	-0.76
Altman Z-Score	10.30	9.26	5.89	7.06	6.92	9.70	11.95	14.63	18.03	18.97	14.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.56	7.73	7.56	6.40	8.91	7.63	8.52	7.51	6.02	9.07	8.95
Quick Ratio	9.58	6.72	6.20	5.09	7.78	6.65	7.29	6.37	4.95	7.85	7.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-28	-30	-47	-52	-56	-70	-65	-51	-49	-59	-54
Operating Cash Flow to CapEx	-1,311.16%	-2,906.93%	-672.94%	-527.53%	-327.73%	-284.49%	-1,659.10%	-1,508.72%	-7,642.28%	-2,759.03%	-924.84%
Free Cash Flow to Firm to Interest Expense	-18.96	-7.37	-52.78	-54.40	-54.97	-62.14	-62.47	-49.67	-42.80	-60.78	-61.68
Operating Cash Flow to Interest Expense	-13.64	-6.10	-40.55	-29.37	-18.59	-22.04	-30.90	-15.28	-16.49	-33.43	-19.36
Operating Cash Flow Less CapEx to Interest Expense	-14.68	-6.31	-46.58	-34.93	-24.26	-29.78	-32.76	-16.29	-16.71	-34.64	-21.46
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.18	0.23	0.28	0.35	0.31	0.38	0.47	0.55	0.50	0.48	0.55
Accounts Receivable Turnover	6.40	7.60	6.17	4.61	4.90	4.28	4.08	3.83	3.86	3.40	3.68
Inventory Turnover	1.86	1.82	1.68	1.77	1.73	1.91	1.81	1.85	1.83	1.82	1.79
Fixed Asset Turnover	11.31	10.95	10.33	9.79	7.24	7.28	7.73	8.02	7.45	8.10	8.80
Accounts Payable Turnover	6.14	6.64	6.68	7.45	5.61	5.69	7.12	8.00	5.94	7.43	7.46
Days Sales Outstanding (DSO)	57.07	48.02	59.18	79.13	74.42	85.29	89.57	95.18	94.67	107.20	99.15
Days Inventory Outstanding (DIO)	196.34	200.60	217.11	206.71	210.71	191.34	202.11	197.50	199.41	200.30	204.22
Days Payable Outstanding (DPO)	59.46	54.95	54.61	49.02	65.04	64.13	51.25	45.63	61.47	49.14	48.94
Cash Conversion Cycle (CCC)	193.94	193.66	221.67	236.82	220.08	212.51	240.43	247.05	232.61	258.37	254.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	25	26	46	57	63	75	92	89	96	120	126
Invested Capital Turnover	3.29	3.90	2.65	2.58	2.66	2.71	2.28	2.42	2.52	2.30	2.29
Increase / (Decrease) in Invested Capital	12	13	27	35	38	49	46	32	33	45	35
Enterprise Value (EV)	1,653	1,686	1,147	1,493	1,249	1,911	2,323	2,979	4,015	3,920	2,931
Market Capitalization	1,849	1,858	1,274	1,592	1,486	2,116	2,496	3,142	4,161	4,202	3,194
Book Value per Share	$4.95	$4.41	$3.86	$3.46	$6.61	$5.56	$5.18	$4.88	$4.64	$7.71	$7.10
Tangible Book Value per Share	$4.92	$4.37	$3.83	$3.43	$6.58	$5.54	$5.15	$4.86	$4.63	$7.69	$7.08
Total Capital	274	248	227	207	351	332	317	303	293	454	443
Total Debt	53	51	54	51	51	51	53	51	51	51	53
Total Long-Term Debt	51	51	51	51	51	51	51	51	51	51	51
Net Debt	-196	-171	-128	-99	-237	-206	-173	-163	-145	-282	-263
Capital Expenditures (CapEx)	1.51	0.87	5.34	5.37	5.78	8.72	1.95	1.04	0.25	1.17	1.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	15	15	34	44	39	47	67	65	73	95	100
Debt-free Net Working Capital (DFNWC)	264	237	216	194	327	305	292	279	269	429	416
Net Working Capital (NWC)	262	237	213	194	327	305	291	279	269	429	414
Net Nonoperating Expense (NNE)	7.14	11	8.62	7.35	6.70	6.81	6.60	6.85	5.28	5.06	5.53
Net Nonoperating Obligations (NNO)	-196	-171	-128	-99	-237	-206	-173	-163	-145	-282	-263
Total Depreciation and Amortization (D&A)	0.70	0.66	0.79	0.64	1.05	1.32	1.18	1.27	1.33	1.45	1.48
Debt-free, Cash-free Net Working Capital to Revenue	24.16%	19.60%	40.28%	42.90%	33.89%	34.82%	42.64%	36.79%	36.32%	42.31%	39.94%
Debt-free Net Working Capital to Revenue	430.22%	316.39%	253.55%	190.95%	281.23%	223.69%	186.94%	158.03%	134.77%	190.96%	166.87%
Net Working Capital to Revenue	426.20%	316.39%	250.03%	190.95%	281.23%	223.69%	185.85%	158.03%	134.77%	190.96%	166.07%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.51)	($0.63)	($0.63)	($0.56)	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	44.64M	44.40M	45.07M	45.16M	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M
Adjusted Diluted Earnings per Share	($0.51)	($0.63)	($0.63)	($0.56)	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	44.64M	44.40M	45.07M	45.16M	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.72M	44.87M	45.05M	45.28M	50.50M	50.96M	51.42M	51.93M	52.18M	54.82M	55.33M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-18	-20	-18	-18	-21	-19	-19	-16	-14	-19
Normalized NOPAT Margin	-76.04%	-73.72%	-81.40%	-54.19%	-51.07%	-47.48%	-43.45%	-35.20%	-26.90%	-20.22%	-27.77%
Pre Tax Income Margin	-111.13%	-118.48%	-116.72%	-76.38%	-70.14%	-63.11%	-58.28%	-48.03%	-35.93%	-27.63%	-35.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.54	-5.83	-31.15	-25.20	-23.16	-23.45	-23.84	-23.88	-17.40	-18.46	-27.21
NOPAT to Interest Expense	-10.63	-4.25	-22.42	-18.59	-17.59	-18.39	-18.52	-18.23	-13.77	-14.24	-21.90
EBIT Less CapEx to Interest Expense	-15.58	-6.04	-37.17	-30.77	-28.84	-31.20	-25.70	-24.89	-17.61	-19.67	-29.30
NOPAT Less CapEx to Interest Expense	-11.68	-4.46	-28.45	-24.15	-23.26	-26.14	-20.38	-19.25	-13.99	-15.45	-23.99
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

PROCEPT BioRobotics (NASDAQ:PRCT) Financial Summary and Trends Analysis (Last Four Years)

Analyzing the most recent quarterly data alongside the past three years of financials reveals several key trends and developments for PROCEPT BioRobotics:

Revenue growth is consistent and strong, with quarterly operating revenue increasing from about $24 million in Q1 2023 to nearly $69 million in Q1 2025, indicating expanding sales and market adoption.
Gross profit has improved substantially, rising proportionally with revenue—from approximately $12.5 million (Q1 2023) to $44.2 million (Q1 2025), suggesting better scale and potential operating leverage.
Cash & equivalents have grown significantly, increasing from around $181 million (Q1 2023) to over $316 million (Q1 2025), reflecting strong cash position and liquidity.
Total assets have nearly doubled over four years—from about $284 million (Q1 2023) to $519 million (Q1 2025), highlighting company expansion and investment in operations.
Common equity has grown, from approximately $173 million (Q1 2023) to $389 million (Q1 2025), showing strengthening shareholder base but significant retained earnings deficits remain.
Operating expenses have been increasing; while revenue growth is evident, expense growth is still outpacing revenue, with total operating expenses rising from about $40.9 million (Q1 2023) to $71.6 million (Q1 2025), indicating ongoing investment in growth and R&D.
R&D expenses remain a significant portion of operating costs (around $10.7 million in Q1 2023 to $16.4 million in Q1 2025), consistent with the company's focus on innovation but pressure on profitability.
PROCEPT BioRobotics continues to report net losses each quarter, with net income moving from a loss of roughly $28.5 million (Q1 2023) to a loss of approximately $24.7 million (Q1 2025). Although losses slightly decreased, profitability remains a concern.
Operating cash flow remains negative, with net cash used in operating activities fluctuating around $16.0 million to $36.0 million per quarter, reflecting significant cash burn to support operations.
Increasing interest expense and long-term debt levels (long-term debt around $51 million) add to financial costs and leverage risks amid continuing losses.

Detailed Observations:

Quarterly revenue showed a robust upward trajectory: approximately +193% growth comparing Q1 2023 ($24.4M) to Q1 2025 ($69.2M).
Cash and equivalents increased by about 75% from Q1 2023 ($181M) to Q1 2025 ($316M), supporting liquidity for R&D and expansion.
Total liabilities have risen from $111 million (Q1 2023) to $130 million (Q1 2025), indicating moderate increase but manageable relative to asset growth.
Despite revenue growth, net losses persist with EPS roughly steady negative: Q1 2023 diluted EPS at -$0.63 compared to Q1 2025 diluted EPS at -$0.45, showing limited movement towards profitability.
Operating expenses scaling faster (+75% Y/Y) than revenue (+51% Y/Y from Q4 2024 to Q1 2025), with SG&A expenses rising sharply in recent quarters, suggesting investment in sales, marketing, or infrastructure.
Interest expenses remain significant (~$0.9 million quarterly), coupled with increased debt balances, indicating financial leverage burden.
Negative operating cash flows (e.g., -$17M in Q1 2025) imply continued cash consumption in operations requiring funding through equity or debt issuance.

Summary:

PROCEPT BioRobotics demonstrates strong top-line growth and increasing operational scale with steadily rising revenues and gross profit over the last four years. However, the company continues to operate at a net loss with negative operating cash flow, highlighting an ongoing need for capital to fund growth and operations.

While liquidity remains solid due to a growing cash balance, management needs to focus on controlling operating expenses and drive profitability. The sizable R&D investments and SG&A spending reflect growth strategies, but these also weigh on near-term earnings and cash flow.

Retail investors should be aware that PROCEPT BioRobotics is still in its growth and investment phase, with improving fundamentals but persistent losses and cash burn. Prospects for turning profitable will depend on continued revenue growth, cost management, and efficient capital deployment.

09/12/25 06:33 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About PROCEPT BioRobotics' Financials

When does PROCEPT BioRobotics' financial year end?

According to the most recent income statement we have on file, PROCEPT BioRobotics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has PROCEPT BioRobotics' net income changed over the last 4 years?

PROCEPT BioRobotics' net income appears to be on an upward trend, with a most recent value of -$91.41 million in 2024, rising from -$53.02 million in 2020. The previous period was -$105.90 million in 2023. Find out what analysts predict for PROCEPT BioRobotics in the coming months.

What is PROCEPT BioRobotics' operating income?

PROCEPT BioRobotics' total operating income in 2024 was -$96.61 million, based on the following breakdown:

Total Gross Profit: $137.10 million
Total Operating Expenses: $233.71 million

How has PROCEPT BioRobotics' revenue changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' total revenue changed from $7.72 million in 2020 to $224.50 million in 2024, a change of 2,809.1%.

How much debt does PROCEPT BioRobotics have?

PROCEPT BioRobotics' total liabilities were at $131.80 million at the end of 2024, a 6.3% increase from 2023, and a 102.7% increase since 2020.

How much cash does PROCEPT BioRobotics have?

In the past 4 years, PROCEPT BioRobotics' cash and equivalents has ranged from $100.13 million in 2020 to $333.73 million in 2024, and is currently $333.73 million as of their latest financial filing in 2024.

How has PROCEPT BioRobotics' book value per share changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' book value per share changed from -49.93 in 2020 to 7.71 in 2024, a change of -115.4%.

Related Companies

This page (NASDAQ:PRCT) was last updated on 9/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About PROCEPT BioRobotics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Financials

Annual Income Statements for PROCEPT BioRobotics

Quarterly Income Statements for PROCEPT BioRobotics

Annual Cash Flow Statements for PROCEPT BioRobotics

Quarterly Cash Flow Statements for PROCEPT BioRobotics

Annual Balance Sheets for PROCEPT BioRobotics

Quarterly Balance Sheets for PROCEPT BioRobotics

Annual Metrics And Ratios for PROCEPT BioRobotics

Quarterly Metrics And Ratios for PROCEPT BioRobotics

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About PROCEPT BioRobotics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools